PURPOSE: Choline derivatives labelled with positron emitters are successfully used for PET imaging of prostate cancer patients. Since little is known about uptake mechanisms, the aim of this study was to characterize choline uptake in prostate cancer cells, also following anti-androgen treatment or chemotherapy. METHODS: Choline uptake in prostate cancer cells (LNCaP, PC-3) and Michaelis-Menten kinetics were analysed using different concentrations of (3)H-choline via liquid scintillation counting. Inhibition of (3)H-choline uptake was assayed in the presence of hemicholinium-3 (HC-3), unlabelled choline, guanidine and tetraethylammonium (TEA), an inhibitor of the organic cation transporter (OCT). Changes in choline uptake triggered by bicalutamide and docetaxel were evaluated and choline transporters were detected via Western blotting. RESULTS: Michaelis-Menten kinetics yielded a saturable transport with K(m) values of 6.9 and 7.0 micromol/l choline for LNCaP and PC-3 cells, respectively. Treatment of cells with bicalutamide and docetaxel caused an increase in total choline uptake but had no significant effect on K(m) values. Uptake of (3)H-choline was NaCl dependent and 4.5-fold higher in LNCaP cells than in PC-3 cells. (3)H-Choline uptake was reduced by 92-96% using HC-3 and unlabelled choline, by 63-69% using guanidine and by 20% using TEA. The high-affinity choline transporter was detected via Western blotting. CONCLUSION: Choline uptake in prostate cancer cells is accomplished both by a transporter-mediated and a diffusion-like component. Results of inhibition experiments suggest that uptake is mediated by a selective choline transporter rather than by the OCT. Bicalutamide- and docetaxel-induced changes in total choline uptake could affect PET tumour imaging.
PURPOSE:Choline derivatives labelled with positron emitters are successfully used for PET imaging of prostate cancerpatients. Since little is known about uptake mechanisms, the aim of this study was to characterize choline uptake in prostate cancer cells, also following anti-androgen treatment or chemotherapy. METHODS:Choline uptake in prostate cancer cells (LNCaP, PC-3) and Michaelis-Menten kinetics were analysed using different concentrations of (3)H-choline via liquid scintillation counting. Inhibition of (3)H-choline uptake was assayed in the presence of hemicholinium-3 (HC-3), unlabelled choline, guanidine and tetraethylammonium (TEA), an inhibitor of the organic cation transporter (OCT). Changes in choline uptake triggered by bicalutamide and docetaxel were evaluated and choline transporters were detected via Western blotting. RESULTS: Michaelis-Menten kinetics yielded a saturable transport with K(m) values of 6.9 and 7.0 micromol/l choline for LNCaP and PC-3 cells, respectively. Treatment of cells with bicalutamide and docetaxel caused an increase in total choline uptake but had no significant effect on K(m) values. Uptake of (3)H-choline was NaCl dependent and 4.5-fold higher in LNCaP cells than in PC-3 cells. (3)H-Choline uptake was reduced by 92-96% using HC-3 and unlabelled choline, by 63-69% using guanidine and by 20% using TEA. The high-affinity choline transporter was detected via Western blotting. CONCLUSION:Choline uptake in prostate cancer cells is accomplished both by a transporter-mediated and a diffusion-like component. Results of inhibition experiments suggest that uptake is mediated by a selective choline transporter rather than by the OCT. Bicalutamide- and docetaxel-induced changes in total choline uptake could affect PET tumour imaging.
Authors: V Gorboulev; J C Ulzheimer; A Akhoundova; I Ulzheimer-Teuber; U Karbach; S Quester; C Baumann; F Lang; A E Busch; H Koepsell Journal: DNA Cell Biol Date: 1997-07 Impact factor: 3.311
Authors: U Haberkorn; I Morr; F Oberdorfer; M E Bellemann; J Blatter; A Altmann; B Kahn; G van Kaick Journal: J Nucl Med Date: 1994-11 Impact factor: 10.057
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers Journal: Nat Med Date: 2003-12-21 Impact factor: 53.440
Authors: H Christian Rischke; Teresa Beck; Werner Vach; Gesche Wieser; Anca L Grosu; Wolfgang Schultze-Seemann; Philipp T Meyer; Cordula A Jilg Journal: Eur J Nucl Med Mol Imaging Date: 2014-06-21 Impact factor: 9.236
Authors: Kimy M Emonds; Johannes V Swinnen; Wytske M van Weerden; Frank Vanderhoydonc; Johan Nuyts; Luc Mortelmans; Felix M Mottaghy Journal: Eur J Nucl Med Mol Imaging Date: 2011-07-06 Impact factor: 9.236
Authors: Daniela E Oprea-Lager; Mitchell P van Kanten; Reindert J A van Moorselaar; Alfons J M van den Eertwegh; Peter M van de Ven; Irene V Bijnsdorp; Otto S Hoekstra; Albert A Geldof Journal: Mol Imaging Biol Date: 2015-06 Impact factor: 3.488
Authors: Vera Graute; Nathalie Jansen; Christopher Ubleis; Michael Seitz; Markus Hartenbach; Michael Karl Scherr; Sven Thieme; Paul Cumming; Katharina Klanke; Reinhold Tiling; Peter Bartenstein; Marcus Hacker Journal: Eur J Nucl Med Mol Imaging Date: 2011-11-16 Impact factor: 9.236
Authors: Peijin Han; Aurelian Bidulescu; John R Barber; Steven H Zeisel; Corinne E Joshu; Anna E Prizment; Mara Z Vitolins; Elizabeth A Platz Journal: Cancer Causes Control Date: 2019-03-01 Impact factor: 2.506
Authors: Susan Evans-Axelsson; David Ulmert; Anders Örbom; Pernilla Peterson; Olle Nilsson; Johan Wennerberg; Joanna Strand; Karin Wingårdh; Tomas Olsson; Zandra Hagman; Vladimir Tolmachev; Anders Bjartell; Hans Lilja; Sven-Erik Strand Journal: Cancer Biother Radiopharm Date: 2012-04-10 Impact factor: 3.099
Authors: Sarah Marie Schwarzenböck; Jana Gertz; Michael Souvatzoglou; Jens Kurth; David Sachs; Roman Nawroth; Uwe Treiber; Tibor Schuster; Reingard Senekowitsch-Schmidtke; Markus Schwaiger; Sibylle Ilse Ziegler; Gjermund Henriksen; Hans-Jürgen Wester; Bernd Joachim Krause Journal: Mol Imaging Biol Date: 2015-04 Impact factor: 3.488
Authors: Cordula A Jilg; Vanessa Drendel; H Christian Rischke; Teresa I Beck; Kathrin Reichel; Malte Krönig; Ulrich Wetterauer; Wolfgang Schultze-Seemann; Philipp T Meyer; Werner Vach Journal: J Nucl Med Date: 2019-01-25 Impact factor: 10.057